News headlines about Oxford Immunotec Global (NASDAQ:OXFD) have trended positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.4304402212754 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of OXFD stock traded down $0.15 during trading hours on Wednesday, reaching $13.09. The company’s stock had a trading volume of 169,625 shares, compared to its average volume of 221,580. The company has a market capitalization of $350.57, a price-to-earnings ratio of -9.05 and a beta of -0.21. The company has a current ratio of 5.37, a quick ratio of 4.92 and a debt-to-equity ratio of 0.34. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.51.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02. The business had revenue of $25.03 million for the quarter, compared to analyst estimates of $25.12 million. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) earnings per share. equities research analysts expect that Oxford Immunotec Global will post -0.9 earnings per share for the current year.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.11% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This article was originally published by BBNS and is the property of of BBNS. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/2018/03/21/positive-media-coverage-somewhat-unlikely-to-affect-oxford-immunotec-global-oxfd-stock-price/1923089.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.